IN171745B - - Google Patents

Info

Publication number
IN171745B
IN171745B IN821/CAL/90A IN821CA1990A IN171745B IN 171745 B IN171745 B IN 171745B IN 821CA1990 A IN821CA1990 A IN 821CA1990A IN 171745 B IN171745 B IN 171745B
Authority
IN
India
Application number
IN821/CAL/90A
Other languages
English (en)
Inventor
Rudolf Edgar Dr Falk
Samuel Simon Dr Asculai
Original Assignee
Norpharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4140639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN171745(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Norpharmco Inc filed Critical Norpharmco Inc
Publication of IN171745B publication Critical patent/IN171745B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
IN821/CAL/90A 1989-09-21 1990-09-21 IN171745B (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA000612307A CA1340994C (fr) 1989-09-21 1989-09-21 Traitement de maladies et d'etats pathologiques

Publications (1)

Publication Number Publication Date
IN171745B true IN171745B (fr) 1992-12-26

Family

ID=4140639

Family Applications (1)

Application Number Title Priority Date Filing Date
IN821/CAL/90A IN171745B (fr) 1989-09-21 1990-09-21

Country Status (26)

Country Link
US (14) US6069135A (fr)
EP (2) EP0656213B1 (fr)
JP (1) JP3256761B2 (fr)
KR (1) KR920700697A (fr)
CN (1) CN1101228C (fr)
AP (1) AP175A (fr)
AT (2) ATE227587T1 (fr)
AU (3) AU6433090A (fr)
BR (1) BR9006924A (fr)
CA (2) CA1340994C (fr)
DE (2) DE69024039T3 (fr)
DK (2) DK0445255T4 (fr)
ES (2) ES2080837T5 (fr)
FI (1) FI912470A7 (fr)
HK (1) HK44797A (fr)
HU (2) HU220758B1 (fr)
IL (1) IL95745A (fr)
IN (1) IN171745B (fr)
LT (1) LT3545B (fr)
NO (1) NO911952L (fr)
RO (1) RO112812B1 (fr)
RU (1) RU2146139C1 (fr)
SG (1) SG49658A1 (fr)
SK (1) SK459890A3 (fr)
WO (1) WO1991004058A2 (fr)
ZA (1) ZA907564B (fr)

Families Citing this family (248)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340994C (fr) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Traitement de maladies et d'etats pathologiques
AU7312291A (en) * 1990-02-13 1991-09-03 Gere S. Dizerega Peritoneal induced medicaments
CA2061566C (fr) * 1992-02-20 2002-07-09 Rudolf E. Falk Traitement des maladies par l'acide hyaluronique et des ains
CA2061703C (fr) * 1992-02-20 2002-07-02 Rudolf E. Falk Compositions renfermant de l'acide hyaluronique
US5639738A (en) * 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
US5733891A (en) * 1990-10-18 1998-03-31 Shiseido Co., Ltd. Compound for medicinal ingredient and hyaluronic acid and process for producing the same
EP0506976B1 (fr) * 1990-10-18 1997-04-09 Shiseido Company Limited Combinaison d'acide hyaluronique avec un ingredient medicinal et sa production
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
EP0503583A1 (fr) * 1991-03-12 1992-09-16 Takeda Chemical Industries, Ltd. Composition à libération prolongée à base d'erythropoiètine
US5416071A (en) * 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
US6432405B1 (en) * 1991-03-15 2002-08-13 Duke University Method of inhibiting HIV infection with CD44 and anti-CD44 antibodies
CA2122519C (fr) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Traitement du cancer et prevention des metastases
US6022866A (en) * 1991-07-03 2000-02-08 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5817644A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Targeting of dosages of medicine and therapeutic agents
US5990095A (en) * 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
CA2079205C (fr) * 1992-09-25 1998-02-10 Rudolf Edgar Falk Utilisation de l'acide hyaluronique et de formules pour empecher la restenose arterielle
WO1994007505A1 (fr) * 1991-07-03 1994-04-14 Norpharmco Inc. Utilisation de l'acide hyaluronique sous differentes formes contre la recidive de la stenose arterielle
ATE173405T1 (de) * 1991-07-10 1998-12-15 Takeda Chemical Industries Ltd Arzneimittel auf basis von hyaluronsäure
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
CA2061567C (fr) * 1992-02-20 1998-02-03 Rudolf E. Falk Utilisation de l'acide hyaluronique pour reparer les dommages de reperfusion de l'ischemie
CA2130762C (fr) * 1994-08-24 1999-07-06 Eva Anne Turley Traitement des maladies et des troubles associes a l'infiltration par des macrophages
US5438075A (en) 1993-03-30 1995-08-01 Skubitz; Keith M. Oral glutamine to reduce stomatitis
CA2094203A1 (fr) * 1993-04-16 1994-10-17 Derek A. Willoughby Inhibition de l'angiogenese
DE69403966T3 (de) * 1993-07-19 2008-04-17 Angiotech Pharmaceuticals, Inc., Vancouver Anti-angiogene mittel und verfahren zu deren verwendung
JPH10504828A (ja) * 1994-08-30 1998-05-12 ハイアル ファーマスティカル コーポレイション 細胞活性調整のためのヒアルロン酸およびその誘導体
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
AU4467396A (en) 1994-12-12 1996-07-10 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
KR100517210B1 (ko) * 1994-12-12 2006-06-07 오메로스 코포레이션 통증,염증및경련억제용관주용액
RU2180852C2 (ru) * 1994-12-12 2002-03-27 Омерос Медикл Системс, Инк. Ингибирующий раствор и способ подавления боли, воспаления или спазма
CA2154103C (fr) * 1995-07-18 1998-02-24 Samuel Simon Asculai Traitement des maladies, traumatismes ou troubles de la membrane muqueuse, et pour le soulagement de la douleur
CA2229282C (fr) * 1995-09-28 2002-01-29 Sangstat Medical Corporation Utilisation d'acide hyaluronique en qualite d'agent immunosuppresseur
NZ320006A (en) * 1995-10-23 2001-12-21 Meditech Res Ltd An adjuvant composition comprising hyaluronic acid for gene therapy either in the sense or antisense direction
US5652273A (en) * 1995-11-30 1997-07-29 Henry; James Reduction of hair growth
HUP9901935A3 (en) * 1995-12-01 2001-04-28 Jagotec Ag Dosage kit for targeting of dosages of medicine and therapeutic agents and other glycosaminoglycans (gags)
US6413961B1 (en) 1995-12-12 2002-07-02 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
CA2166155C (fr) * 1995-12-27 2008-02-05 Eva Anne Turley Liaison d'agents aux domaines de liaison de l'acide hyaluronique et son utilisation
EP0873128B1 (fr) 1996-01-11 2004-11-17 Jagotec Ag Administration orale de quantites efficaces de formes de l'acide hyaluronique
US6875753B1 (en) * 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
US20050101564A1 (en) * 1996-04-02 2005-05-12 Pilarski Linda M. Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
US5939047A (en) * 1996-04-16 1999-08-17 Jernberg; Gary R. Local delivery of chemotherapeutic agents for treatment of periodontal disease
US6787530B1 (en) * 1996-08-23 2004-09-07 Monash University Use of pregnane-diones as analgesic agents
DE69732308T2 (de) * 1996-09-27 2005-06-02 Jagotec Ag Arzneistoffverabreichungssystem mit hyaluronsäure
US6451784B1 (en) * 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
CA2205692A1 (fr) * 1997-05-16 1998-11-16 Hyal Pharmaceutical Corporation Methode pour administrer un agent therapeutique, utilisant des formes appropriees d'acide hyaluronique en combinaison avec l'electroporation
CA2205771C (fr) * 1997-05-22 2002-05-14 Hyal Pharmaceutical Corporation Administration amelioree pour traitement de fond
US6123957A (en) * 1997-07-16 2000-09-26 Jernberg; Gary R. Delivery of agents and method for regeneration of periodontal tissues
US5938658A (en) * 1997-12-02 1999-08-17 Tu; Hosheng Device and methods for treating canker sores by RF ablation
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US7070799B1 (en) 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
BR9909393A (pt) 1998-04-03 2000-12-26 Ajinomoto Kk Agente antitumor, uso de um derivado de estilbeno e um composto de coordenação de platina, e, processo para o tratamento ou melhoramento de um tumor
US7799766B2 (en) * 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US6984667B2 (en) * 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
GB9810127D0 (en) * 1998-05-13 1998-07-08 Ml Lab Plc Prevention of surgical adhesions
US6391861B1 (en) 1998-05-14 2002-05-21 The Trustees Of Columbia University In The City Of New York Method for the prevention of tissue elastic fiber injury
US6663874B2 (en) 1998-11-02 2003-12-16 Victor Stevens Composition to alleviate pain and topical method of applying same
ATE245410T1 (de) * 1998-12-23 2003-08-15 Esparma Gmbh Mittel zum schutz der haut enthaltend hydrolysierte hyaluronsäure
AU773984B2 (en) * 1999-01-13 2004-06-10 Alchemia Oncology Pty Limited A composition and method for the enhancement of the efficacy of drugs
EP1140198B1 (fr) * 1999-01-13 2007-10-31 Alchemia Oncology Pty Limited Utilisation d'hyaluronan pour la preparation d'un medicament a accroitre l'efficacite des agents cytotoxiques
JP2002536323A (ja) * 1999-02-04 2002-10-29 ジェンザイム コーポレーション 膿瘍形成の予防
WO2000050058A1 (fr) * 1999-02-26 2000-08-31 Marcus Keep Composition pharmaceutique cerebrospinale et vasculaire et procede de preparation de ladite composition
CA2374003C (fr) * 1999-05-17 2008-02-12 Aesgen, Inc. Assimilation cellulaire amelioree d'agents bioactifs
JP4450456B2 (ja) * 1999-09-27 2010-04-14 株式会社マルハニチロ水産 皮脂産生抑制剤
SE9904121D0 (sv) * 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
DE60036019T2 (de) * 1999-12-13 2008-05-29 Bioniche Life Sciences Inc., Belleville Synthetische oligonukleotide die therapeutisch nützlich sind
US7125858B2 (en) * 1999-12-28 2006-10-24 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
GB0003048D0 (en) * 2000-02-11 2000-03-29 Dealler Stephen F The therapeutic use of polysulphonated polyglycosides or other polyanionic compounds in autism
PT1142566E (pt) * 2000-04-07 2004-02-27 Medidom Lab Formulacao oftalmica topica na forma de uma solucao aquosa e uso de uma ciclosporina em associacao com acido hialuronico ou um de seus sais e com polisorbato 80
US6926898B2 (en) * 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
AU2001264817A1 (en) * 2000-05-23 2001-12-17 Exhale Therapeutics, Inc. Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of clycosaminoglycans
US6221166B1 (en) 2000-06-07 2001-04-24 Simplus Systems Corporation Multi-thermal zone shielding apparatus
WO2002030432A1 (fr) * 2000-06-23 2002-04-18 Cambridgemed, Inc Agent pour reduire la formation de cicatrices par alcalinisation de plaies
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US7285284B2 (en) * 2000-09-08 2007-10-23 Kuhnau Stephen C Cosmetic composition, method of use and method of making
AU2001292929A1 (en) * 2000-09-26 2002-04-08 Temple University Of The Commonwealth System Of Higher Education Analgesic and glucosamine compositions
US6924273B2 (en) * 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
CZ20031262A3 (en) * 2000-10-16 2004-03-17 Neopharm, Inc. Liposomal formulation of mitoxantrone
WO2002040021A2 (fr) * 2000-11-17 2002-05-23 Idenix (Cayman) Limited Procedes d'inhibition de la transmission du vih au moyen de 6-benzyl-4-oxopyrimidines substituees a application topique
CN1131036C (zh) * 2001-02-28 2003-12-17 中国人民解放军第三军医大学 N－乙酰－d－氨基葡萄糖在制备抑制放化疗副反应药物中的应用
US20060198815A1 (en) * 2001-03-19 2006-09-07 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained release
US20020172712A1 (en) * 2001-03-19 2002-11-21 Alan Drizen Antiemetic, anti-motion sustained release drug delivery system
JP2005511477A (ja) * 2001-03-19 2005-04-28 プラエシス ファーマシューティカルズ インコーポレーテッド 持続放出のための医薬調合物
JP5024497B2 (ja) * 2001-03-27 2012-09-12 キユーピー株式会社 経口用肌改善剤、肌改善方法及び肌改善用食品組成物
RU2284818C2 (ru) * 2001-05-10 2006-10-10 Анормед, Инк. Комбинированная химиотерапия
US8403954B2 (en) 2001-05-22 2013-03-26 Sanostec Corp. Nasal congestion, obstruction relief, and drug delivery
WO2002097038A2 (fr) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Proteines hybrides beta-1 de chimiokine
RU2191012C1 (ru) * 2001-06-20 2002-10-20 Научно-исследовательский испытательный центр (медико-биологической защиты) Государственного научно-исследовательского испытательного института военной медицины МО РФ Глазные капли для лечения эндотелиально-эпителиальной дистрофии роговицы
US20030027867A1 (en) * 2001-06-29 2003-02-06 Myriad Genetics, Incorporated Use of R-NSAID compounds for anti-HIV treatment
CN100542612C (zh) * 2001-08-14 2009-09-23 特拉维夫大学未来技术研发有限公司 类脂化糖胺聚糖颗粒及其在诊断和治疗用药物和基因传递中的应用
MXPA04001828A (es) * 2001-08-27 2005-03-07 Meditech Res Ltd Protocolos terapeuticos mejorados.
AU2002325635C1 (en) * 2001-08-27 2008-09-25 Alchemia Oncology Pty Limited Improved therapeutic protocols
US7354910B2 (en) * 2001-10-18 2008-04-08 Seikagaku Kogyo Kabushiki Kaisha Agent for treating inflammatory bowel diseases
EP1443944A1 (fr) * 2001-11-12 2004-08-11 Johannes Reinmüller Applications pharmaceutiques de preparations a l'acide hyaluronique
US6806259B2 (en) * 2001-12-21 2004-10-19 Soft Gel Technologies, Inc. Hyaluronic Acid in soft gel form
CA2841097A1 (fr) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumine et proteines hybrides g-csf
WO2005003296A2 (fr) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Proteines hybrides d'albumine
RU2213557C2 (ru) * 2001-12-26 2003-10-10 Закрытое акционерное общество "Аксис" Фармацевтическая композиция, обладающая тромболитическими, противовоспалительными и цитопротективными свойствами
RU2232581C2 (ru) * 2002-02-05 2004-07-20 ООО НКЦ ОиН "Биотерапия" СПОСОБ ОПТИМИЗАЦИИ ПРОЦЕДУРЫ ОБЩЕЙ УПРАВЛЯЕМОЙ ГИПЕРТЕРМИИ С ТЕМПЕРАТУРОЙ РАЗОГРЕВА 43-44єC ПУТЕМ ИЗМЕРЕНИЯ ПРОТОКОЛА ХИМИОТЕРАПИИ
US6887270B2 (en) 2002-02-08 2005-05-03 Boston Scientific Scimed, Inc. Implantable or insertable medical device resistant to microbial growth and biofilm formation
US7993390B2 (en) * 2002-02-08 2011-08-09 Boston Scientific Scimed, Inc. Implantable or insertable medical device resistant to microbial growth and biofilm formation
US8506647B2 (en) * 2002-02-14 2013-08-13 Boston Scientific Scimed, Inc. System for maintaining body canal patency
EP1480656A4 (fr) * 2002-02-15 2007-07-18 Res Dev Foundation Tranduction adenovirale induite par l'acide hyaluronique
FR2836336B1 (fr) 2002-02-26 2004-08-27 Diana Ingredients Utilisation dans un traitement cosmetique d'une fraction phenolique riche en dihydrochalcones
AU2003217982A1 (en) * 2002-03-06 2003-09-22 The Medical Research And Education Trust Botanical extract compositions with anti-cancer or phytoestrogenic activity comprising wogonin, isoliquiritigenin and/or coumestrol
RU2222261C2 (ru) * 2002-03-22 2004-01-27 Ростовский научно-исследовательский онкологический институт Способ прицельной внутриорганной химиотерапии больных раком тела матки
RU2209634C1 (ru) * 2002-04-29 2003-08-10 Иткес Александр Веньяминович Набор эстроген-рецептор для обнаружения рецепторов к эстрогенам в биопсийных гистологических препаратах (варианты)
JP2005530768A (ja) * 2002-05-09 2005-10-13 メディジーンズ 血漿または血清を含有した創傷治療用医薬組成物
ITMI20020986A1 (it) * 2002-05-10 2003-11-10 Acraf Composizione a base di diclofenac per il trattamento topico di affezioni del cavo orofaringeo
US20060094643A1 (en) * 2002-07-03 2006-05-04 Yuri Svirkin Compositions of hyaluronic acid and methods of use
NZ538405A (en) * 2002-08-01 2007-12-21 Aesgen Inc Improved treatment of cancer with glutamine and carbohydrate
US20040253296A1 (en) * 2002-09-11 2004-12-16 Martin Kenneth A. Food bar for treating musculoskeletal disorders
US20040253227A1 (en) * 2002-09-11 2004-12-16 Martin Kenneth A. Perioperative multivitamin protein beverage and additive for use in preparing an individual for fast surgical recovery
US6660308B1 (en) 2002-09-11 2003-12-09 Kenneth A. Martin Beverage and additive for the ill
US20040254095A1 (en) * 2002-09-11 2004-12-16 Martin Kenneth A. Supplement for treating musculoskeletal disorders
US6900173B2 (en) * 2002-09-11 2005-05-31 Kenneth A. Martin Perioperative multivitamin protein bar for use in preparing an individual for fast surgical recovery
US6979458B1 (en) 2002-09-11 2005-12-27 Kenneth A. Martin Beverage and additive for wellness
DE10246340A1 (de) * 2002-10-04 2004-04-29 Wohlrab, David, Dr. Kombinationspräparat aus Hyaluronsäure und mindestens einem Lokalanästhetikum und dessen Verwendung
EP1603548A4 (fr) * 2003-02-05 2007-10-10 Myriad Genetics Inc Composition et methode de traitement de troubles neurodegeneratifs
US6946551B2 (en) 2003-03-12 2005-09-20 New Life Resources, Llc Preparation of hyaluronic acid from eggshell membrane
US20080063677A1 (en) * 2004-03-10 2008-03-13 New Life Resources, Llc Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations
US20040180025A1 (en) * 2003-03-12 2004-09-16 New Life Resources, Llc Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations
US20050136126A1 (en) * 2003-03-17 2005-06-23 Cambridgemed, Inc. Agent for reduction of scar formation by using wound alkalinization
RU2233658C1 (ru) * 2003-03-24 2004-08-10 Нижегородская государственная медицинская академия Способ профилактики кардиальных осложнений общей гипертермии с полихимиотерапией у больных с запущенными формами рака
JP4212970B2 (ja) * 2003-06-30 2009-01-21 株式会社キーエンス 安全リレーシステム
WO2005065069A2 (fr) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Procedes pharmaceutiques, posologies et formes posologiques pour le traitement de la maladie d'alzheimer
US6913968B2 (en) * 2003-07-30 2005-07-05 International Business Machines Corporation Method and structure for vertical DRAM devices with self-aligned upper trench shaping
US8236794B2 (en) * 2003-09-29 2012-08-07 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of mesothelioma
WO2005032417A2 (fr) * 2003-09-30 2005-04-14 Synthes (Usa) Revetements d'acide hyaluronique antimicrobiens pour implants orthopediques
HUP0303313A2 (hu) * 2003-10-09 2005-07-28 Richter Gedeon Vegyészeti Gyár Rt. Transzdermális gyógyszerkészítmények
US20050196455A1 (en) * 2003-10-27 2005-09-08 Jianbing Chen Suspension delivery system for the sustained and controlled local release of pharmaceuticals
US20050100537A1 (en) * 2003-11-10 2005-05-12 Evans Gregory S. Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals
US20050147570A1 (en) * 2004-01-06 2005-07-07 Nordsiek Michael T. Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne
WO2005070333A1 (fr) * 2004-01-13 2005-08-04 Orthobiologica, Inc. Administration d'un medicament a une articulation
DE102004002001A1 (de) * 2004-01-14 2005-08-11 Reinmüller, Johannes, Dr.med. Mittel zur Behandlung von entzündlichen Erkrankungen
US20050186269A1 (en) * 2004-02-25 2005-08-25 Udell Ronald G. Stabilized feverfew formulations
US8580315B2 (en) * 2004-03-10 2013-11-12 Esm Technologies, Llc Anti-inflammatory activity of eggshell membrane and processed eggshell membrane preparations
US7699783B2 (en) * 2004-04-08 2010-04-20 Techniscan, Inc. Method for imaging and treating a breast
WO2006001877A2 (fr) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Composition pharmaceutique et methode de traitement de troubles neurodegeneratifs
AR051429A1 (es) * 2004-04-20 2007-01-17 Stenti De Pirillo Haydee A Composicion farmaceutica ozonizada y metodos para obtenerla
WO2005108683A1 (fr) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Placages pour parois, murs de soutenement et analogues
DE102004030155B4 (de) * 2004-06-22 2020-04-23 Robert Bosch Gmbh Dosiervorrichtung und Verfahren zum Betrieb derselben
CA2570570A1 (fr) * 2004-06-22 2006-01-05 Pro-Pharmaceuticals, Inc. Compositions et procedes pour la codelivrance de medicaments anticancereux, de medicaments anti-angiogeniques, et d'un polysaccharide
WO2006020852A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
WO2006020850A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
CA2618985A1 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et methode de traitement de troubles neurodegeneratifs
AU2005272578A1 (en) * 2004-08-13 2006-02-23 Angiotech International Ag Compositions and methods using hyaluronic acid and hyluronidase inhibitors
US7414021B2 (en) * 2004-10-01 2008-08-19 Vincent Carmine Giampapa Method and composition for restoration of age related tissue loss in the face or selected areas of the body
RU2259204C1 (ru) * 2004-10-12 2005-08-27 Открытое Акционерное Общество "Нижегородский Химико-Фармацевтический Завод" (Оао "Нижфарм") Средство для лечения болезней суставов
MX2007006833A (es) 2004-12-10 2007-10-08 Talima Therapeutics Inc Composiciones y metodos para tratar condiciones de la unidad de una.
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
US20060292250A1 (en) * 2005-06-23 2006-12-28 Suracell, Inc. Supplement composition and method of use for enhancement of anti-inflammation process
US7276257B2 (en) * 2005-07-22 2007-10-02 The Hong Kong University Of Science And Technology Schisandrin B preparation
CA2615063A1 (fr) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. Formes posologiques et preparations a charge medicamenteuse elevee
CA2616607C (fr) * 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Protocoles therapeutiques utilisant hyaluronan
RU2292203C1 (ru) * 2005-08-17 2007-01-27 Общество с ограниченной ответственностью Медицинский центр "Эллара" (ООО МЦ "Эллара") Средство для лечения болезней суставов
US7323184B2 (en) * 2005-08-22 2008-01-29 Healagenics, Inc. Compositions and methods for the treatment of wounds and the reduction of scar formation
US20070048391A1 (en) * 2005-08-23 2007-03-01 Cambridgemed, Inc. Composition for reduction of scar formation on wound scar
US8319625B2 (en) * 2005-09-01 2012-11-27 Simplexgrinnell Lp Fire alarm textual notification related application
EP1922077A4 (fr) * 2005-09-07 2013-03-06 Alchemia Oncology Pty Ltd Compositions thérapeutiques comprenant de l hyaluronane et des anticorps therapeutiques, et procédes thérapeutiques
AU2006287485B2 (en) * 2005-09-07 2012-07-12 Amo Regional Holdings Bi-modal hyaluronate solution
US8598144B1 (en) 2005-11-10 2013-12-03 Reyn Pharma, Llc Method of administering hyaluronan formulation for the amelioration of osteoarthritis
US9492381B1 (en) 2005-11-10 2016-11-15 Reyn Pharma, Llc Method of administering hyaluronan formulation for preventing and ameliorating osteoarthritis
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US7722665B2 (en) * 2006-07-07 2010-05-25 Graft Technologies, Inc. System and method for providing a graft in a vascular environment
EP2046119A2 (fr) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Traitement de troubles psychiatriques
CA2662581C (fr) 2006-09-13 2018-01-30 Enhance Skin Products, Inc. Composition cosmetique pour le traitement de la peau et procedes correspondants
CN101541830A (zh) * 2006-09-22 2009-09-23 诺沃-诺迪斯克有限公司 蛋白酶抗性的胰岛素类似物
US20100210792A1 (en) * 2006-12-05 2010-08-19 David Taft Drug delivery
AU2006352358B2 (en) * 2006-12-26 2014-03-13 Bomi Patel Framroze Skin lightening composition for hyperpigmented skin
US8466128B2 (en) 2007-01-30 2013-06-18 Cypress Pharmaceuticals, Inc. Hyaluronate compositions
ES2373867T3 (es) * 2007-03-02 2012-02-09 The University Of Wollongong Composiciones y procedimientos para el suministro de agentes anticancerosos.
US20080268039A1 (en) * 2007-03-06 2008-10-30 Soft Gel Technologies, Inc. Loquat compositions
ES2858224T3 (es) * 2007-05-15 2021-09-29 QT Ultrasound LLC Sistema de exploración de senos
DK3354276T3 (da) 2007-11-13 2020-03-30 Meritage Pharma Inc Sammensætninger til behandlingen af gastrointestinal inflammation
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090143343A1 (en) * 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
ITMI20080284A1 (it) * 2008-02-22 2009-08-23 Indena Spa Agenti antitumorali a struttura benzofenantridinica e formulazioni che li contengono
CN101970477B (zh) 2008-03-14 2014-12-31 诺沃-诺迪斯克有限公司 蛋白酶稳定的胰岛素类似物
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
US8163716B1 (en) 2008-06-30 2012-04-24 Smith James D Method of administering hyaluronan formulation for the amelioration of osteophytes
US8178511B1 (en) 2008-07-02 2012-05-15 Smith James D Method of administering hyaluronan formulation for the amelioration of osteopenia
IT1397247B1 (it) * 2009-05-14 2013-01-04 Fidia Farmaceutici Nuovi agenti regolatori dell'attivita' citochinica
GB0913442D0 (en) 2009-07-31 2009-09-16 Univ Ramot Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
US8273725B2 (en) * 2009-09-10 2012-09-25 Genzyme Corporation Stable hyaluronan/steroid formulation
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
WO2012018597A2 (fr) 2010-07-26 2012-02-09 Chemotherapeutics, Llc Compositions et procédés d'amélioration de l'efficacité des traitements systémiques, hipec et ip contre le cancer
US8398611B2 (en) 2010-12-28 2013-03-19 Depuy Mitek, Inc. Compositions and methods for treating joints
US8455436B2 (en) 2010-12-28 2013-06-04 Depuy Mitek, Llc Compositions and methods for treating joints
US8524662B2 (en) 2010-12-28 2013-09-03 Depuy Mitek, Llc Compositions and methods for treating joints
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
RU2624239C2 (ru) 2011-06-03 2017-07-03 Аллерган, Инк. Составы кожного наполнителя, включая антиоксиданты
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
TW201249843A (en) * 2011-06-14 2012-12-16 Univ Kaohsiung Medical Processes for preparing amine salts of KMUP-3 and use thereof
US8623839B2 (en) 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
HUE037474T2 (hu) * 2011-07-07 2018-08-28 Holy Stone Healthcare Co Ltd Készítmény gyulladással kapcsolatban rendellenesség kezelésében és megelõzésében történõ alkalmazásra
US20150359798A1 (en) * 2011-09-06 2015-12-17 Jansfat Biotechnology Co., Ltd. Piperazinyl derivative reduces high-fat diet-induced accumulation of fat in the livers, therapeutically
EP2567697A1 (fr) 2011-09-12 2013-03-13 Almirall, S.A. Compositions pharmaceutiques topiques
TWI466675B (zh) * 2011-09-16 2015-01-01 Univ China Medical 用於抑制發炎之醫藥組合物
GB201118198D0 (en) 2011-10-21 2011-12-07 Jagotec Ag Improvements in or relating to organic compounds
GB201118193D0 (en) 2011-10-21 2011-12-07 Jagotec Ag Improvements in or relating to oranic compounds
EP2782584B1 (fr) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Préparations et thérapies de substitution pour hormonothérapie naturelle combinée
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RU2497200C1 (ru) * 2012-03-28 2013-10-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Способ фармакологической коррекции ишемии скелетной мышцы миноксидилом
RU2497201C1 (ru) * 2012-03-28 2013-10-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Способ увеличения выживаемости кожного лоскута в условиях редуцированного кровообращения миноксидилом
WO2013156989A1 (fr) 2012-04-18 2013-10-24 Ramot At Tel-Aviv University Ltd. Particules de glycosaminoglycane lipidé pour la libération d'acides nucléiques
ITPD20120173A1 (it) 2012-05-31 2013-12-01 Fidia Farmaceutici "nuovo sistema di rilascio di proteine idrofobiche"
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
ITMI20121316A1 (it) 2012-07-27 2014-01-28 Altergon Sa Complessi di condroitina ad assorbimento transcutaneo
FR2994846B1 (fr) 2012-08-29 2014-12-26 Vivacy Lab Composition, sterilisee, comprenant au moins un acide hyaluronique et de l'ascorbyl phosphate de magnesium
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
FR3000670B1 (fr) * 2013-01-10 2015-02-27 Oreal Composition cosmetique apaisante a base d'acide salicylique.
CN105377355A (zh) 2013-03-14 2016-03-02 拇趾公司 治疗甲单元的感染、疾病或病症的方法
EP2981283A4 (fr) 2013-04-03 2017-07-05 Cedars-Sinai Medical Center Traitement des affections inflammatoires par modulation de l'activité hyaluronane et hyaluronidase
GR1008308B (el) 2013-05-31 2014-10-02 UNI-PHARMA ΚΛΕΩΝ ΤΣΕΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ ΑΒΕΕ με δ.τ. "UNI-PHARMA ABEE", Τοπικες φαρμακευτικες και ιατροτεχνολογικες συνθεσεις που περιεχουν συνδυασμους σουκραλφατης, υαλουρονικου οξεος, αργινινης και ενος φυσικου ενυδατικου παραγοντα
KR101439032B1 (ko) * 2013-06-13 2014-09-05 동아에스티 주식회사 피록시캄과 히알루론산을 포함하는 골관절염 치료를 위한 액상 조성물
CN103330945B (zh) * 2013-07-16 2014-07-02 山东大学齐鲁医院 平阳霉素联合透明质酸钠在治疗淋巴管畸形药物中的应用
CN103341157A (zh) * 2013-07-25 2013-10-09 山东大学齐鲁医院 平阳霉素联合透明质酸钠在治疗静脉畸形药物中的应用
CA2926701A1 (fr) 2013-10-07 2015-04-16 Novo Nordisk A/S Nouveau derive d'un analogue de l'insuline
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
JP2017520549A (ja) 2014-06-26 2017-07-27 ラモット アット テル アビブ ユニバーシティ， リミテッド 核酸の送達のためのリポソーム製剤
US9682099B2 (en) 2015-01-20 2017-06-20 DePuy Synthes Products, Inc. Compositions and methods for treating joints
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (fr) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Compositions d'hormones stéroïdes dans des huiles à chaîne moyenne
ES2886837T3 (es) 2016-12-16 2021-12-21 Novo Nordisk As Composiciones farmacéuticas que contienen insulina
WO2019173261A1 (fr) * 2018-03-06 2019-09-12 Samuel Asculai Composition et procédé de traitement du cancer à l'aide d'acide hyaluronique
CN109512825A (zh) * 2018-12-29 2019-03-26 江苏靶标生物医药研究所有限公司 一种铂类化合物和透明质酸钠的组合物及其应用
CN110467689A (zh) * 2019-09-09 2019-11-19 山东众山生物科技有限公司 一种透明质酸衍生物及其制备方法
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2583096A (en) * 1949-01-15 1952-01-22 Searle & Co Process for the production of high viscosity hyaluronic acid
GB769287A (en) * 1954-08-18 1957-03-06 American Home Prod Preparation of partially depolymerized hyaluronic acid and therapeutic compositions thereof
FR3715M (fr) * 1964-06-11 1965-11-29 Lucien Nouvel Antithermiques et antirhumatismaux améliorés.
US3887703A (en) * 1967-03-24 1975-06-03 Oreal Mucopolysaccharides, their preparation and use in cosmetic and pharmaceutical compositions
GB1283892A (en) * 1970-06-08 1972-08-02 Irwin Irville Lubowe Improvements in and relating to medicinal compositions for application to the skin and/or hair
DE2364373A1 (de) * 1973-12-22 1975-07-10 Hahn Carl Dr Gmbh Pharmazeutische und kosmetische praeparate zur aeusserlichen anwendung
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4282216A (en) * 1977-04-20 1981-08-04 Johnson & Johnson Topical anti-inflammatory drug therapy
US4296104A (en) * 1979-08-30 1981-10-20 Herschler R J Therapeutic dimethyl sulfoxide composition and methods of use
US4272522A (en) * 1979-10-15 1981-06-09 Balazs Endre A Method for stimulating phagocytic activity and synergistic compositions therefor
US4303676A (en) * 1980-03-21 1981-12-01 Balazs Endre A Hyaluronate based compositions and cosmetic formulations containing same
US4434177A (en) * 1980-04-14 1984-02-28 Merck & Co., Inc. α-Methyldopa-L-ascorbic acid compositions
JPS57183707A (en) * 1981-05-02 1982-11-12 Shiseido Co Ltd Cosmetic
US4684627A (en) * 1981-09-08 1987-08-04 Leveen Harry H Treatment of cancer with phlorizin and its derivatives
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US4582685A (en) 1982-10-07 1986-04-15 Helena Laboratories Corporation Test kit for performing a medical test
US4711884A (en) * 1983-02-28 1987-12-08 E. R. Squibb & Sons, Inc. Thiazine and thiazepine containing compounds
AU555747B2 (en) * 1983-08-09 1986-10-09 Cilco Inc. Chondroitin sulfate and sodium hyaluronate composition
AU570998B2 (en) * 1983-09-07 1988-03-31 Takeda Chemical Industries Ltd. Topical steroid compositions for acne
CH666897A5 (fr) * 1983-10-11 1988-08-31 Fidia Spa Fractions d'acide hyaluronique non inflammatoire, procedes et compositions pharmaceutiques.
IL74715A0 (en) * 1984-03-27 1985-06-30 Univ New Jersey Med Biodegradable matrix and methods for producing same
CH663353A5 (de) * 1984-03-28 1987-12-15 Joaquin Amat Larraz Mittel gegen krebs.
US4716224A (en) * 1984-05-04 1987-12-29 Seikagaku Kogyo Co. Ltd. Crosslinked hyaluronic acid and its use
JPS6117A (ja) * 1984-06-11 1986-01-06 Seikagaku Kogyo Co Ltd ムコ多糖系癌転移抑制剤
US4711780A (en) * 1984-06-11 1987-12-08 Fahim Mostafa S Composition and process for promoting epithelial regeneration
US4735902A (en) * 1984-10-23 1988-04-05 Matti Siren Stabilized composition containing inositoltriphosphate
US4582865A (en) * 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4636524A (en) * 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
EP0187703B1 (fr) * 1985-01-11 1992-08-05 Teijin Limited Préparations à libération prolongée
JPS61233622A (ja) * 1985-04-09 1986-10-17 Riken Vitamin Co Ltd 眼薬組成物
SE8501723L (sv) * 1985-04-09 1986-10-10 Pharmacia Ab Preparation att anvendas vid behandling av ledinflammation
US4725585A (en) * 1985-04-26 1988-02-16 Pharmacia Ab Method of enhancing the host defense
US4725852A (en) 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
IT1214609B (it) * 1985-05-17 1990-01-18 Opocrin Spa Esosaminoglicani solfati depolimerizzati ad attivita'antitrombotica, fibrinolitica, antinfiammatoria, loro procedimento di preparazione e composizioni farmaceutiche che li contengono.
EP0207638B1 (fr) * 1985-06-04 1990-12-19 Teijin Limited Préparation pharmaceutique à liberation prolongé
US4617319A (en) * 1985-06-13 1986-10-14 American Cyanamid Company Method of treating multiple sclerosis
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
FR2584606A1 (fr) * 1985-07-12 1987-01-16 Dropic Utilisation de poly- et oligosaccharides pour l'obtention de medicaments actifs dans les pathologies du tissu conjonctif
IN166447B (fr) * 1985-11-27 1990-05-12 Ethicon Inc
EP0224987B1 (fr) * 1985-11-29 1992-04-15 Biomatrix, Inc. Systèmes à base de l'hyaluronanne, de ses dérivés et de ses sels pour la libération de médicaments et leur procédé de fabrication
JP2604135B2 (ja) * 1986-02-28 1997-04-30 ライオン株式会社 口腔骨疾患治療剤
US5262403A (en) * 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
JPS62212335A (ja) * 1986-03-14 1987-09-18 Mitsui Toatsu Chem Inc ２−アリ−ル−２−メチルプロピルエ−テル誘導体およびそれを有効成分として含有する殺虫剤
JPS62240628A (ja) * 1986-03-26 1987-10-21 Kao Corp 経皮吸収促進剤およびこれを含有する外用剤
EP0240098A3 (fr) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo et Polysaccharides pour le traitement des maladies causées par des rétrovirus
JPS6345223A (ja) * 1986-04-04 1988-02-26 Ueno Seiyaku Oyo Kenkyusho:Kk ひと免疫不全ウイルス性疾患処置剤
US4808576A (en) * 1986-04-28 1989-02-28 Mobay Corporation Remote administration of hyaluronic acid to mammals
AU604236B2 (en) * 1986-04-28 1990-12-13 Iolab, Inc. Intraocular dosage compositions and method of use
JPH06104624B2 (ja) * 1986-05-07 1994-12-21 太郎 小木曽 経皮吸収剤
IT1189111B (it) * 1986-05-08 1988-01-28 Minnesota Mining & Mfg Elementi radiografici con un ridotto cross-over e ridotta colorazione residua
JPS62287041A (ja) * 1986-06-05 1987-12-12 Kawasaki Steel Corp 高合金鋼焼結材料の製造方法
US4946870A (en) * 1986-06-06 1990-08-07 Union Carbide Chemicals And Plastics Company Inc. Delivery systems for pharmaceutical or therapeutic actives
JPS6311678A (ja) 1986-06-30 1988-01-19 Hitachi Chem Co Ltd 無電解銅めつき法
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
IT1198449B (it) * 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
JPH07110349B2 (ja) * 1986-11-04 1995-11-29 セイレイ工業株式会社 籾摺選別装置
ZA878877B (en) * 1986-11-29 1988-05-24 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Treatment of diseases caused by viruses
EP0270319A3 (fr) * 1986-12-03 1990-03-28 Logistics Data Systems, Inc. Système vidéo pour C.A.O.
US5385938B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
GB8706052D0 (en) * 1987-03-13 1987-04-15 Medical Research Int Therapeutic compositions
ATE129254T1 (de) * 1987-03-19 1995-11-15 Arthropharm Pty Ltd Antientzündungsmittel und zusammensetzungen.
EP0285357A3 (fr) * 1987-03-31 1989-10-25 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Lutte contre les rétrovirus
US4795741A (en) * 1987-05-06 1989-01-03 Biomatrix, Inc. Compositions for therapeutic percutaneous embolization and the use thereof
US5079236A (en) * 1987-05-27 1992-01-07 Hyal Pharmaceutical Corporation Pure, sterile, pyrogen-free hyaluronic acid formulations their methods of preparation and methods of use
GB8713662D0 (en) * 1987-06-11 1987-07-15 Skandigen Ab Hyaluronic acid derivatives
GB8713747D0 (en) * 1987-06-12 1987-07-15 Unilever Plc Skin treatment composition
GB8715242D0 (en) * 1987-06-29 1987-08-05 Wood E M Fenclofenac as immunosuppressant drug
JP2756131B2 (ja) * 1987-07-01 1998-05-25 ジェネンテク，インコーポレイテッド フィブリンの沈着または癒着の予防のための方法および治療学的組成物
US4900550A (en) * 1987-08-19 1990-02-13 Amy Allene Cosmetiques, Inc. Skin care cosmetic regime
WO1989001772A1 (fr) * 1987-09-03 1989-03-09 University Of Georgia Research Foundation, Inc. Composition de cyclosporine oculaire
ATE90205T1 (de) * 1987-09-08 1993-06-15 Takeda Chemical Industries Ltd Wasserunloesliche cytokine.
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
HU203198B (en) * 1987-10-26 1991-06-28 Sandoz Ag Process for producing pharmaceutical compositions having immunity-inhibiting, monokin-, particularly interleukin-1-inhibiting effect
JPH01151462A (ja) * 1987-12-09 1989-06-14 Terumo Corp 腹膜灌流液
DK505488D0 (da) * 1987-12-21 1988-09-09 Bar Shalom Daniel Middel og anvendelse af samme
DK505588D0 (da) * 1988-02-26 1988-09-09 Jesper Hamburger Middel og anvendelse af samme
US4943560A (en) * 1988-04-06 1990-07-24 Regents Of The University Of Minnesota Solvent system for chronic vascular infusion of hydrophobic drugs
JPH01265970A (ja) * 1988-04-19 1989-10-24 Shiseido Co Ltd ヒアルロン酸を含有させたコラーゲン水溶液又は水分散液
US4840341A (en) 1988-05-09 1989-06-20 Hasegawa Gary K Clip and holder
IT1219587B (it) * 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
JPH01287041A (ja) * 1988-05-13 1989-11-17 Rooman Kogyo:Kk 徐放性製剤
US5135915A (en) * 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
DE3900198A1 (de) * 1989-01-05 1990-07-12 Merck Patent Gmbh Topisch anwendbare pharmazeutische zubereitung
US5032384A (en) * 1989-01-27 1991-07-16 Block Drug Company, Inc. Compositions and method for the treatment of disease
US5156846A (en) * 1989-02-23 1992-10-20 University Of Utah Percutaneous drug delivery system
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5053222A (en) * 1989-06-07 1991-10-01 Shiseido Company Ltd. Hair cosmetic composition
CA1340994C (fr) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Traitement de maladies et d'etats pathologiques
US5095037B1 (en) * 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
US5181276A (en) * 1990-02-22 1993-01-26 Baxter International Inc. Infection resistant products
US5290271A (en) * 1990-05-14 1994-03-01 Jernberg Gary R Surgical implant and method for controlled release of chemotherapeutic agents
US5091182A (en) * 1990-07-23 1992-02-25 Syntex (U.S.A.) Inc. Dispensing units for ketorolac topical gel formlations
US5234914A (en) * 1991-06-11 1993-08-10 Patent Biopharmaceutics, Inc. Methods of treating hemorrhoids and anorecial disease
DK0555087T3 (da) * 1992-02-04 1999-05-03 Baxter Int Peritoneale dialyseopløsninger indeholdende mindst ét dipeptid

Also Published As

Publication number Publication date
AU6433090A (en) 1991-04-18
AU1485097A (en) 1997-05-22
ES2080837T5 (es) 2002-03-01
FI912470A0 (fi) 1991-05-21
NO911952L (no) 1991-07-05
DK0656213T3 (da) 2003-03-17
CN1051503A (zh) 1991-05-22
CA1340994C (fr) 2000-05-16
LT3545B (en) 1995-11-27
FI912470A7 (fi) 1991-05-21
DE69034018T2 (de) 2003-07-24
EP0445255A1 (fr) 1991-09-11
US20040019011A1 (en) 2004-01-29
EP0656213A1 (fr) 1995-06-07
ATE131068T1 (de) 1995-12-15
DK0445255T3 (da) 1996-03-04
JP3256761B2 (ja) 2002-02-12
DE69034018D1 (de) 2002-12-19
HK44797A (en) 1997-04-18
RU2146139C1 (ru) 2000-03-10
WO1991004058A2 (fr) 1991-04-04
RO112812B1 (ro) 1998-01-30
CA2042034A1 (fr) 1991-03-22
AU674894B2 (en) 1997-01-16
US5929048A (en) 1999-07-27
DE69024039D1 (de) 1996-01-18
US6048844A (en) 2000-04-11
JPH04504579A (ja) 1992-08-13
KR920700697A (ko) 1992-08-10
US20060128655A1 (en) 2006-06-15
US6194392B1 (en) 2001-02-27
US5985851A (en) 1999-11-16
US5852002A (en) 1998-12-22
AU5227493A (en) 1994-03-03
DE69024039T2 (de) 1996-06-13
NO911952D0 (no) 1991-05-21
US5932560A (en) 1999-08-03
US5811410A (en) 1998-09-22
SG49658A1 (en) 1998-06-15
SK459890A3 (en) 2000-09-12
CN1101228C (zh) 2003-02-12
HU220758B1 (hu) 2002-05-28
HK1005985A1 (en) 1999-02-05
HU211953A9 (en) 1996-01-29
HUT64699A (en) 1994-02-28
ES2080837T3 (es) 1996-02-16
LTIP1582A (en) 1995-06-26
US5914314A (en) 1999-06-22
ATE227587T1 (de) 2002-11-15
US6069135A (en) 2000-05-30
US5830882A (en) 1998-11-03
DE69024039T3 (de) 2002-12-12
EP0445255B2 (fr) 2001-12-05
IL95745A (en) 1999-09-22
AP9000206A0 (en) 1990-10-31
EP0656213B1 (fr) 2002-11-13
AU674894C (en) 2002-03-14
EP0445255B1 (fr) 1995-12-06
DK0445255T4 (da) 2002-02-18
US5827834A (en) 1998-10-27
IL95745A0 (fr) 1991-06-30
AP175A (en) 1992-04-03
WO1991004058A3 (fr) 1991-09-19
ZA907564B (en) 1991-08-28
BR9006924A (pt) 1991-12-10
HU907339D0 (en) 1991-08-28
US5985850A (en) 1999-11-16
ES2186693T3 (es) 2003-05-16

Similar Documents

Publication Publication Date Title
FR2651483B1 (fr)
DK0479920T3 (fr)
DE4090565T (fr)
EP0426507A3 (fr)
DE4091925T (fr)
EP0477369A4 (fr)
DE4091980T (fr)
DE4091170T (fr)
DE4090376A1 (fr)
DE4090652T (fr)
DK0415647T3 (fr)
DE4090165T (fr)
FR2655409B1 (fr)
DE4091977T (fr)
DE4090770T (fr)
DE4091714T (fr)
FR2644855B3 (fr)
DE3991694T (fr)
DK0491704T3 (fr)
DE4092222T (fr)
FR2641714B1 (fr)
AU638668B2 (fr)
FR2647582B1 (fr)
FR2636293B1 (fr)
AU1896788A (fr)